BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December 30, 2009 POLICY STATEMENT Code Company · honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; · SEC · compliance with applicable governmental laws, rules, and regulations; · the prompt internal reporting to the appropriate person of violations of this Code;] [BIOSTAR PHARMACEUTICALS, INC. To: [Director Name] [Address] Dear [Director Name]: Company This is to confirm the terms of your appointment as a Non-Executive Director and as [_____] of Biostar Pharmaceuticals, Inc. (the “ Board Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the " By accepting this appointment, you have confirmed that] [Biostar Pharmaceuticals Strengthens Corporate Governance with Appointments of New Independent Directors, Establishment of Board Committees and Adoption of Code of Ethics Xi’an, China – January 4, 2010 – , today announced a series of measures adopted to strengthen the Company’s corporate governance in compliance with the listing requirements of a senior U.S. exchange. December 30, 2009. First, two directors, Mr.]

By | 2016-03-03T14:59:43+00:00 January 5th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December

[BIOSTAR PHARMACEUTICALS, INC. CODE OF ETHICS Dated: December 30, 2009 POLICY STATEMENT Code Company · honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; · SEC · compliance with applicable governmental laws, rules, and regulations; · the prompt internal reporting to the appropriate person of violations of this Code;] [BIOSTAR PHARMACEUTICALS, INC. To: [Director Name] [Address] Dear [Director Name]: Company This is to confirm the terms of your appointment as a Non-Executive Director and as [_____] of Biostar Pharmaceuticals, Inc. (the “ Board Overall, in terms of time commitment, we expect your attendance at all the Board of Directors (the " By accepting this appointment, you have confirmed that] [Biostar Pharmaceuticals Strengthens Corporate Governance with Appointments of New Independent Directors, Establishment of Board Committees and Adoption of Code of Ethics Xi’an, China – January 4, 2010 – , today announced a series of measures adopted to strengthen the Company’s corporate governance in compliance with the listing requirements of a senior U.S. exchange. December 30, 2009. First, two directors, Mr.]

By | 2016-03-03T15:00:43+00:00 January 5th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany honest and ethicalnduct,luding the ethical handling of actual or apparentnflicts of interest between personal and professional relationships; SECmpliance with applicable governmental laws, rules, and regulations; the prompt internal reporting to the appropriate person of violations of thisde; and] [BIOSTAR PHARMACEUTICALS, To: [Director Name] [Address] Dear [Director Name]:mpany This is tonfirm the terms of your appointment a Non-Executive Director and [_____] of Biostar Pharmaceuticals, (the Board Overall, in terms of timemmitment, we expect your attendance atl the Board of Directors (the "] [Biostar Pharmaceuticals Strengthensrporate Governance with Appointments of New Independent Directors, Establishment of Boardmmittees andoption ofde of Ethics Xian, China January 4, 2010 , today announced a series of measuresopted to strengthen thempanysrporate governance inmpliance with the listing requirements of a senior U.S. exchange.]

By | 2016-02-07T17:45:41+00:00 January 5th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany

[BIOSTAR PHARMACEUTICALS,DE OF ETHICSted:December 30, 2009 POLICY STATEMENTdempany honest and ethicalnduct,luding the ethical handling of actual or apparentnflicts of interest between personal and professional relationships; SECmpliance with applicable governmental laws, rules, and regulations; the prompt internal reporting to the appropriate person of violations of thisde; and] [BIOSTAR PHARMACEUTICALS, To: [Director Name] [Address] Dear [Director Name]:mpany This is tonfirm the terms of your appointment a Non-Executive Director and [_____] of Biostar Pharmaceuticals, (the Board Overall, in terms of timemmitment, we expect your attendance atl the Board of Directors (the "] [Biostar Pharmaceuticals Strengthensrporate Governance with Appointments of New Independent Directors, Establishment of Boardmmittees andoption ofde of Ethics Xian, China January 4, 2010 , today announced a series of measuresopted to strengthen thempanysrporate governance inmpliance with the listing requirements of a senior U.S. exchange.]

By | 2016-02-07T17:46:39+00:00 January 5th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

CSUN [China Sunergy] SC 13G: (Original Filing)

[CUSIP No. 1 Frederick L. Ransier, as Receiver* * Due to the powers and authority conferred by the Orders (defined below) upon the Receiver, the Receiver may be deemed to have beneficial ownership of the American Depository Shares of China Sunergy Co., Ltd. and the ordinary shares of China Sunergy Co., Ltd. represented by such American Depository Shares. NAME OF]

By | 2016-03-07T14:34:33+00:00 January 5th, 2010|Categories: Chinese Stocks, CSUN, SEC Original|Tags: , , , , , |0 Comments

CSUN [China Sunergy] SC 13G: CUSIP No. 1 Frederick L. Ransier, as Receiver*

[CUSIP No. 1 Frederick L. Ransier, as Receiver* * Due to the powers and authority conferred by the Orders (defined below) upon the Receiver, the Receiver may be deemed to have beneficial ownership of the American Depository Shares of China Sunergy Co., Ltd. and the ordinary shares of China Sunergy Co., Ltd. represented by such American Depository Shares. NAME OF]

By | 2016-03-07T14:35:49+00:00 January 5th, 2010|Categories: Chinese Stocks, CSUN, Webplus ver|Tags: , , , , , |0 Comments

GSOL [GLOBAL SOURCES] 6-K: (Original Filing)

[FOR IMMEDIATE RELEASE Global Sources Press Contact in Asia: Global Sources Investor Contact in Asia: Camellia So Investor Relations Department Tel: (852) 2555-5021 Tel: (852) 2555-4777 c so@globalsources.com e-mail: inves t or@globalsources.c o m e-mail: Global Sources Press Contact in U.S.: Global Sources Investor Contact in U.S.: James W.W. Strachan Kirsten Chapman & Timothy Dien Tel: (1 480) 664 8309]

By | 2016-03-07T20:25:40+00:00 January 5th, 2010|Categories: Chinese Stocks, GSOL, SEC Original|Tags: , , , , , |0 Comments

GSOL [GLOBAL SOURCES] 6-K: FOR IMMEDIATE RELEASE Global Sources Press Contact in

[FOR IMMEDIATE RELEASE Global Sources Press Contact in Asia: Global Sources Investor Contact in Asia: Camellia So Investor Relations Department Tel: (852) 2555-5021 Tel: (852) 2555-4777 c so@globalsources.com e-mail: inves t or@globalsources.c o m e-mail: Global Sources Press Contact in U.S.: Global Sources Investor Contact in U.S.: James W.W. Strachan Kirsten Chapman & Timothy Dien Tel: (1 480) 664 8309]

By | 2016-03-07T20:26:55+00:00 January 5th, 2010|Categories: Chinese Stocks, GSOL, Webplus ver|Tags: , , , , , |0 Comments

EDS [Exceed Co] SC TO-I/A: SCHEDULE TO (Amendment No. 2) (Rule 14d-100) Tender

[SCHEDULE TO (Amendment No. 2) (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) EXCEED COMPANY LTD. (Name of Subject Company (Issuer)) EXCEED COMPANY LTD. (Names of Filing Persons (Issuer)) (Title of Class of Securities) G32335112 (CUSIP Number of Class of Securities) Lin Shuipan Chairman and Chief Executive Officer Suite 8, 20/F, One International Finance Centre 1 Harbour View] [SUPPLEMENT NO. 1 DATED JANUARY 5, 2010 TO OFFER LETTER TO PURCHASE ORDINARY SHARES OF EXCEED COMPANY LTD. NOVEMBER 30, 2009 THE OFFER HAS BEEN EXTENDED. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON FRIDAY, FEBRUARY 26, 2010, UNLESS THE OFFER IS FURTHER EXTENDED. Offer to Purchase This Supplement (this “Supplement”) supplements and] [Exceed Company Ltd. Announces Amendment to Exchange th ABOUT EXCEED COMPANY LTD Exceed Company Ltd. designs, develops and engages in wholesale of footwear, apparel and accessories under its own brand, XIDELONG, in China. It is one of the leading domestic sports and leisurewear brands in China in terms of market share by sales revenue. Since operations began in 2002, Exceed]

By | 2016-03-21T04:52:26+00:00 January 5th, 2010|Categories: Chinese Stocks, EDS, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar